Please login to the form below
Fotivda
This page shows the latest Fotivda news and features for those working in and with pharma, biotech and healthcare.
Aveo’s tivozanib is knocked back by FDA once again
EMA to approve the drug as Fotivda in Europe in 2017 based on the TIVO-1 data. ... Fast forward a few years , and Fotivda’s license in Europe is at risk of being withdrawn, and the company’s attempt to file in the US based on TIVO-3
Latest news
-
AVEO warns EU approval of Fotivda could be at risk
Concerns arose with overall survival data. AVEO Oncology has revealed in a regulatory filing that European Medicines Agency (EMA) approval for its Fotivda kidney cancer drug could be at risk of ... revealed a hazard ratio (HR) of 1.12 for Fotivda, in
-
Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on EUSA drug
EUSA’s Fotivda approved for NHS use in Scotland. Specialist pharma company EUSA Pharma has welcomed the Scottish Medicines Consortium approval of its renal cell carcinoma treatment Fotivda (tivozanib).
-
NICE backs EUSA's RCC treatment Fotivda
14% of patients on Fotivda requiring a dose reduction due to adverse events compared to the 43% on Nexavar. ... However, Aveo Oncology is looking to re-file Fotivda in the US pending the results of the TIVO-3 study.
-
EUSA receives European green light for kidney cancer treatment Fotivda
European Commission approves the drug to treat RCC. The European Commission (EC) has approved EUSA Pharma’s vascular endothelial growth factor receptor (VEGFR) inhibitor Fotivda (tivozaniv) as a first-line treatment
-
Samsung Bioepis wins CHMP nod for second Humira biosimilar
got the okay for VEGF receptor inhibitor Fotivda (tivozanib) for the treatment of advanced renal cell carcinoma.
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
Latest appointments
-
EUSA Pharma appoints Rolf Hoffmann to its board
Fotivda in Europe.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- LEO Pharma enters clinical trial partnership with ICON
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Inizio appoints Stefanie Christmas as global head of DE&I
- Rare diseases: not so rare after all
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- A relentless commitment to neuroscience
- Sanofi to acquire Provention Bio in deal worth $2.9bn
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
